3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Breast
1
Conditions
Breast Neoplasms
11
Triple Negative Breast Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease Progression
1
Carcinoma, Renal Cell
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Adenocarcinoma Of Esophagus
1
Interventions
spartalizumab
2
durvalumab
2
zanidatamab
1
tremelimumab
1
trastuzumab deruxtecan
1
tislelizumab
1
pembrolizumab
1
obinutuzumab
1
naptumomab estafenatox
1
Trastuzumab
1
Polymerase Chain Reaction
1
Nivolumab
1
Mass Spectrometry
1
In Situ Hybridization, Fluorescence
1
Immunohistochemistry
1
Gemcitabine
1
Capecitabine
1
Albumin-Bound Paclitaxel
1
Ado-Trastuzumab Emtansine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
tremelimumab
×
Breast
×
Clear all
NCT03982173
2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn